THE PEP PEEPS · RESEARCH LIBRARY
Peptide FAQs: 18 common questions, answered with evidence
Plain-English answers to frequently searched questions about BPC-157, the Wolverine stack, GHK-Cu, retatrutide, NAD+, peptide calculations and mixing. We distinguish animal results from human clinical findings.
1. What are peptides, and are all peptides the same?
Peptides are chains of amino acids. Some are established medicines, such as insulin and certain GLP-1 receptor agonists; others are experimental molecules. Evidence for one peptide cannot be transferred to another.
2. What is BPC-157 and what did animal studies find?
BPC-157 is a synthetic 15-amino-acid peptide. Rat experiments have reported improved tendon-to-bone healing, muscle injury recovery and gastrointestinal tissue protection, with changes in blood-vessel signalling. These are preclinical findings, not proof of the same benefits in people.
3. What is the BPC-157 dose for humans?
There is no validated, regulator-approved human dosing schedule for BPC-157. Animal studies use different doses and routes depending on the model; converting a rat dose directly into a human injection schedule is not scientifically reliable.
4. What is the Wolverine stack?
The Wolverine stack is the informal name for pairing BPC-157 with TB-500. The rationale comes from separate preclinical research on tissue repair and cell migration. No controlled human trial has established that the combination improves injury recovery or is safe.
5. What is TB-500 and how is it different from thymosin beta-4?
TB-500 commonly refers to a short fragment associated with thymosin beta-4, a larger naturally occurring protein involved in actin regulation and cell migration. Research on full-length thymosin beta-4 cannot automatically establish the effects of the shorter fragment.
6. Does GHK-Cu help skin or wound healing?
In rabbit and rat wound models, GHK-related treatments improved measures such as wound closure, collagen deposition and tissue remodelling. Small cosmetic studies suggest possible skin benefits, but formulations differ and robust evidence for injectable human use remains limited.
7. What is a GHK-Cu dose?
There is no established clinical injection dose for GHK-Cu for cosmetic or healing purposes. Topical cosmetics and injectable research preparations are not interchangeable; route, formulation and copper content matter.
8. What does NAD+ do?
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential to cellular energy metabolism, redox reactions and enzymes involved in DNA repair. It is not a peptide. Raising NAD-related biomarkers through precursors does not by itself prove improved longevity or disease outcomes.
9. What is retatrutide (Reta), and what did human trials find?
Retatrutide is an investigational medicine activating GLP-1, GIP and glucagon receptors. Randomised human obesity trials have demonstrated substantial average weight loss under controlled trial conditions, along with gastrointestinal side effects. Trial results do not validate dosing of unregulated products.
10. What is the Reta dosing schedule?
Published retatrutide trials used protocol-defined, gradually escalated once-weekly doses and clinical monitoring; schedules differ across studies. Those are research protocols, not a personal dosing recommendation or evidence that an online research vial matches trial material.
11. How do you calculate peptide concentration after reconstitution?
For laboratory calculations, concentration (mg/mL) equals the stated mass of compound (mg) divided by the final solution volume (mL). Example: 10 mg in 2 mL gives 5 mg/mL. This arithmetic does not confirm identity, sterility, stability or suitability for injection.
12. What is the difference between sterile water and bacteriostatic water?
Sterile water contains no antimicrobial preservative; bacteriostatic water typically contains benzyl alcohol. Neither makes an unverified research product suitable for injection. Appropriate diluent, compatibility, storage and beyond-use dating depend on the specific authorised preparation.
13. Can you mix two peptides in the same vial?
Compatibility cannot be assumed. Peptides can differ in pH requirements, solubility, chemical stability and contamination risks. Without validated compatibility data, mixing compounds can alter the product; a mathematical calculator cannot establish chemical compatibility.
14. How are peptides injected, and are research peptides safe to inject?
Approved injectable peptide medicines have product-specific instructions and trained clinical support. Experimental research peptides may have uncertain purity, sterility and human safety, so there is no universal safe injection method for them. Do not inject laboratory-labelled products.
15. What are common side effects and risks of experimental peptides?
Risks depend on the compound and route. Potential concerns include allergic reactions, infection or contamination, unexpected pharmacological effects and interactions. Animal studies may reveal mechanisms but often cannot detect uncommon or long-term harms in people.
16. Are peptide calculators dosing recommendations?
No. Calculators can convert mass, volume and concentration, but they cannot determine an effective or safe human dose, verify vial contents or replace prescribing information.
17. Can peptides help tendon injuries or muscle recovery?
BPC-157 animal models have reported improvements in certain tendon and muscle healing measures; thymosin beta-4 research also investigates tissue repair. Well-controlled human studies establishing a useful treatment regimen for the popular research blends are lacking.
18. Are peptides legal or approved for human use?
It depends on the particular molecule, jurisdiction, indication and supply route. Some peptide medicines are authorised; many research peptides are not approved for human administration. A research-only label is not evidence of medical approval.
Research references and further reading
For the primary research behind these summaries, see retatrutide phase 2 trial (NEJM), retatrutide phase 3 trial (NEJM, 2026), GHK-Cu review and animal wound studies, soft-tissue regeneration review and BPC-157 human evidence synthesis. Individual studies differ in quality and clinical applicability.